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Abstract: Neurotensin (NT) is a 13-amino acid peptide localized in the neuroendocrine cells of
the small intestine, which promotes fat absorption and fatty acids translocation in response to
lipid ingestion. NT-knock-out mice fed with a high-fat diet are protected from obesity, fatty liver,
and the development of insulin-resistance. In humans, higher plasma levels of pro-NT, which is
the stable circulating precursor of NT, predict obesity, type 2 diabetes (T2D), and cardiovascular
disease. In obesity, the presence of visceral adipose tissue (VAT) inflammation leads to unfavorable
metabolic outcomes and is associated with the development of T2D and non-alcoholic fatty liver
disease (NAFLD). In this study, we investigated the relationship between plasma pro-NT levels
and the presence of VAT inflammation in biopsies from 40 morbidly obese subjects undergoing
bariatric surgery. We demonstrated that higher proNT levels are significantly associated with greater
macrophages infiltration, HIF-1α, WISP-1, and UNC5B expression in VAT (all p < 0.01) due to the
diagnosis of T2D and NAFLD. The overall results show that, in obesity, pro-NT is a biomarker of
VAT inflammation and insulin-resistance. Additionally, NT may be involved in the development
of dysmetabolic conditions likely mediated by increased gut fat absorption and the presence of a
proinflammatory milieu in the adipose tissue.
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1. Introduction
Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small
intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation
to food lipid content [1]. Moreover, NT acts as a neurotransmitter in the central nervous system
by regulating ghrelin and leptin-associated pathways that mediate satiety and food ingestion in the
lateral hypothalamic area [2–4]. Very recently, we demonstrated the existence of a positive association
between NT and leptin levels in the bloodstream, which makes the hypothesis that NT modulates
leptin concentration in periphery through mechanisms involving gut fat absorption more plausible [5].
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Several experimental models show that NT mediates the development of fatty liver disease and
obesity [6–8] while, in humans, large epidemiological studies demonstrate that higher circulating levels
of pro-neurotensin (pro-NT), which is the stable NT precursor released in equimolar amount with NT,
predict obesity, type 2 diabetes (T2D), and cardiovascular disease [9,10]. Obesity-associated diseases
such as insulin-resistance, T2D, and metabolic syndrome (MS) have been associated with adipose
tissue (AT) dysfunction occurring in conditions of chronic excessive caloric intake [11]. Therefore,
the nutrients overload impairs the physiological plasticity of adipocytes, which results in fatty acid spill
over, insufficient neovascularization, necrosis, and recruitment/activation of several immune cells such
as macrophages, dendritic cells, and lymphocytes. Moreover, in obesity, a significant downregulation
of the VAT expression of genes involved in lipid metabolism has been shown. This likely describes a
condition of plateau in the storage capacity of adipocytes, which is not capable to further synthetize
fatty acids [12]. The overall result is chronic AT inflammation, which leads to systemic low-grade
inflammation, increased circulating fatty acids concentration, and insulin-resistance and aberrant
fat deposition in the liver [13–15]. NT and its receptor NTR1 have been recently shown to be
over-expressed in colitis-associated visceral AT (VAT) inflammation [16,17]. NT also stimulates the
preadipocyte-dependent macrophage migration in vitro through a mechanism involving the IL-6
release [17]. The overall data, therefore, points towards a direct role of NT in regulating macrophage
function, which induces inflammatory pathways leading to VAT dysfunction. However, whether NT
is associated with VAT inflammation in obesity and metabolic disease has not yet been investigated.
Therefore, the aim of this study was to investigate the relationship between systemic NT and VAT
inflammation in morbidly obese individuals with and without T2D.
2. Materials and Methods
2.1. Population
For this study, we recruited 40 obese individuals to bariatric surgery referring to the Diabetes
and Endocrinology outpatient clinics, Sapienza University of Rome, Italy, for pre-operative metabolic
evaluations. Study participants were both males and females aged between 25 and 65 years, had clinical
indication to sleeve gastrectomy, and met the following inclusion/exclusion: no history of current
or past excessive alcohol drinking (daily consumption of alcohol >30 g/day in men and >20 g/day
in women), negative tests for hepatitis B and C, absence of history and findings consistent with
cirrhosis and other causes of liver diseases (autoimmune hepatitis, hemochromatosis, Wilson’s disease),
and no treatment with drugs potentially inducing liver steatosis (e.g., corticosteroids, oestrogens,
methotrexate, tetracycline, calcium channel blockers, and amiodarone). All the study participants
signed a written informed consent before undergoing all the study procedures. The study protocol has
been reviewed and approved by the local Ethics Committee and conducted in conformance with the
Helsinki Declaration.
2.2. Clinical and Laboratory Assessments
Study population underwent complete clinical workup including height, weight, and waist
circumference measurement and body mass index calculation (BMI; weight (kg)× height (m2)), systolic
(SBP) and diastolic (DBP) blood pressure were assessed after 5 min of resting, three measurements were
taken, and the average of the second and third measurements was recorded and used for the analyses.
Overnight fasting blood sampling was performed in all the study participants for assessing blood
glucose (FBG, mg/dL), glycosylated hemoglobin (HbA1c, %—mmol/mol), total cholesterol (mg/dL),
high-density lipoprotein cholesterol (HDL, mg/dL), triglycerides (mg/dL), aspartate aminotransferase
(AST, IU/L), alanine aminotransferase (ALT, IU/L), and creatinine (mg/dL) by centralized standard
methods. Fasting blood insulin (FBI, l U/mL) was measured by radioimmunoassay (ADVIA Insulin
Ready Pack 100; Bayer Diagnostics, Milan, Italy) with intra-assay and inter-assay coefficients of
variation <5%. The low-density lipoprotein (LDL) cholesterol value was calculated by the Friedwald
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formula. Insulin resistance and secretion were estimated by calculating the HOMA-IR and HOMA-β
secretion indexes, respectively. Diabetes mellitus was defined by the ADA criteria [18] and the
metabolic syndrome was diagnosed based on the modified NCEP-ATPIII criteria [19]. Circulating
concentration of pro-NT, the stable NT precursor fragment released in equimolar amounts relative to
NT, was measured on plasma frozen immediately after separation and stored at −80 ◦C. Pro-NT was
measured using a chemiluminometric sandwich immunoassay to detect pro-NT amino acids 1–117,
which was described previously [20]. The analytical assay sensitivity was 4.8 pmol proNT/L. The inter
assay (10 assay runs) coefficient of variability was 6.2% at 48 pmol proNT/L and 4.1% at 191 pmol/L.
2.3. Histological and Immunohistochemical Analysis
Histological examinations were performed on omental biopsies (~1 cm3) obtained from patients
undergoing laparoscopic sleeve gastrectomy for clinical purposes. VAT biopsies were fixed with 10%
buffered formalin for 24 h and then paraffin-embedded (FFPE). Hematoxylin and eosin (H&E) stained
sections were performed for histological evaluation and, for all the samples, a consecutive section
(3 µm) was stained with Masson’s trichrome and used for analysis of fibrosis. Two pathologists, blinded
to the experimental protocol, performed the analyses. To evaluate the infiltration of macrophages,
we performed immuno-histochemical analysis using CD68 monoclonal antibody (clone M0876, 1:100;
Dako, Carpinteria, CA, USA) and evaluated changes in micro-vessel density by CD34 immunostaining
(clone QBEnd/10; Leyca Biosystem, Newcastle, UK). From paraffin tissue blocks, AT consecutive
tissue sections (2 µm) were cut and the sections were deparaffinized and rehydrated. Endogenous
peroxidase activity was blocked with 3% hydrogen peroxide and antigen retrieval was made by boiling
them in citrate buffer (0.01 mol/L, pH 6) with microwaves (750 W). The sections were incubated
for 1 h at room temperature (RT) with primary antibodies and universal LSAB2 System-HRP (Dako,
Carpinteria, CA, USA) was used to label the primary antibodies. The samples were then washed
with TBS buffer and incubated with freshly prepared DAB + substrate–chromogen buffer at room
temperature. After gently rinsing with ddH2O, the slides were counterstained with hematoxylin and
mounted with permanent mounting media. Both positive and negative internal and external controls
were used in each experiment. Results were expressed through a semi-quantitative scale by evaluating
the percentage of CD68 positive cells in five random fields (40×) of each sample and then the mean
value was used to define the percentage of positive cells per sample. The stained sections were first
screened at low power (×10) to determine the areas of most intense staining for CD34. Then the blood
vessel counting was performed under ×40 magnification in five random fields.
2.4. Gene Expression Analysis—RealTime PCR
Total RNA from FFPE samples was extracted using RecoverAll™ Total Nucleic Acid Isolation Kit
for FFPE (ThermoFisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions.
Purity and quantity of RNA were confirmed by NanoDrop ND-1000 Spectrophotometer (ThermoFisher
Scientific, Waltham, MA, USA). RNA was reverse transcribed into cDNA with High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA). PCR products of human
NTN1, UNC5B, CAV1, IL8, MIP1A, MIP2, TIMP1, GZMB, CASP3, CASP7, PARP1, HIF1A, and WISP1
were detected by using gene-specific primers and probes labeled with reporter dye FAM. GAPDH was
used as an internal standard, which yielded a predicted amplicon of 171 bp. TaqMan real-time
quantitative PCR was performed on an ABI PRISM 7500 Fast Real-Time PCR System (Applied
Biosystem, Foster City, CA, USA). PCR reactions were carried out in triplicate on 96-well plates
with 10 L per well using 1× TaqMan Master Mix. After 2-min incubation at 50 ◦C and 10 min at
95 ◦C, the reactions continued for 40 cycles at 95 ◦C for 15 s and 60 ◦C for one minute. At the end
of the reaction, the results were evaluated using the ABI PRISM 7500 software (Applied Biosystem,
Foster City, CA, USA). The cycle threshold (Ct) values for each set of 3 reactions were averaged for all
subsequent calculations. The 2−∆Ct method was used to calculate relative changes in gene expression.
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3. Results
In the whole study population, mean ± SD plasma pro-NT concentration was 178.6 ± 85 pmol/L
[median (25–75◦): 159.4 (118–216.9) pmol/L] (Table 1) and positively correlated with greater age
(r = 0.43, p = 0.004), (triglycerides r = 0.39, p = 0.012), (HbA1c r = 0.40, p = 0.012), (FBI r = 0.38, p = 0.02),
with the diagnosis of T2D (r = 0.33, p = 0.039), and the presence and severity of NAFLD evaluated by
the NAS score (r = 0.41, p = 0.01, r = 0.36, p = 0.023; respectively). In contrast, no association was found
between pro-NT, systemic blood pressure, total HDL cholesterol, LDL cholesterol, transaminases, waist
circumference, and BMI. No significant difference was observed between circulating proNT levels in
male and female participants (181.6 ± 87.9 vs. 182.5 ± 90.6 pmol/L, respectively, p = 0.97). All the
bivariate analyses are shown in Table 2.
When considering glucose tolerance, patients with T2D showed significantly higher plasma
proNT levels than non-diabetic individuals (160.9± 87.9 vs. 280.6± 133.7 pmol/L, p = 0.02). Moreover,
the study population was further stratified according to the glycemic state (normo-glycaemia, impaired
fasting glucose (IFG)/impaired glucose tolerance (IGT), and T2D) and we observed that plasma pro-NT
levels significantly increased throughout classes of impaired glucose metabolism (normo-glycaemic
individuals: 155 ± 53.2 pmol/L vs. IFG/IGT: 176.6 ± 90.8 pmol/L vs. T2D: 280.6 ± 133.7 pmol/L;
p < 0.01, ANOVA test applied). Finally, the multivariate linear regression analysis showed that greater
age and triglycerides concentration represented the main predictors of increased circulating proNT
levels after adjusting for BMI, gender, and all the parameters significantly associated with the bivariate
correlation analyses (R = 0.55, R2 = 0.30; p = 0.014).
Higher pro-NT levels were significantly associated with features of VAT inflammation explored
by both immunohistochemistry and VAT gene expression analyses.
In our study population, median (range) CD68+ expression was 2 (0–10)% and median (range)
CD34+ expression was 2 (1–7)%. Greater circulating pro-NT concentration, as expressed by pro-NT
above the median value, was associated with significantly higher CD68+ (CD68+ > median expression,
OR 4.2 (95% C.I.: 2.4–7.2), p < 0.001; Figure 1) and lower CD34+ expression (CD34+ < median expression;
OR 0.2 (95% C.I.: 0.05–0.87), p = 0.03).
Higher pro-NT levels also correlated with increased HIF-1α (r = 0.41, p = 0.011), WISP-1 (r = 0.37,
p = 0.022), and UNC5B (r = 0.42, p = 0.009) expression in VAT (see Table 3).
Table 1. Clinical and biochemical characteristics of the study population.
Parameter Mean± Standard Deviation Rate (%) Median (25◦–75◦ Percentile)
Age (years) 43.7 ± 9.6 42 (38–49)
Gender (M%) 24% -
BMI (kg/m2) 43.6 ± 5.6 42.2 (40–47.4)
Waist circumference (cm) 128 ± 11.4 126 (126–135.5)
SBP (mmHg) 128.3 ± 16.1 130 (120–136)
DBP (mmHg) 84.8 ± 18.2 80 (80–85)
Total Cholesterol (mg/dL) 196 ± 32.4 194.5 (176.2–207)
HDL (mg/dL) 48.2 ± 10.4 48 (39–55)
LDL (mg/dL) 120.3 ± 29.7 120 (120–137)
Triglycerides (mg/dL) 129.5 ± 44.9 127 (127–160)
FBG (mg/dL) 104 ± 22.4 95 (90–120)
HbA1c (%—mmol/mol) 5.9 ± 1 5.3 (5.1–5.8)
FBI (µU/L) 16.8 ± 15.1 11.5 (9.7–16.6)
HOMA-IR 4.5 ± 4.7 2.8 (2.2–4)
HOMA-β% 164 ± 120 133.5 (67.8–212)
Pro-NT (pmol/L) 178.6 ± 85 159.4 (118–216.9)
T2D (%) 15% -
MS (%) 80% -
NAFLD (%) 50% -
NASH (%) 25% -
Therapy with antidiabetic agents 15% -
Therapy with statins 92% -
Therapy with anti-hypertensive medications 73% -
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Table 2. Pro-NT-Bivariate correlation analyses (Pearson’s coefficient, * Spearman’s coefficient, pro-NT
is considered a continuous variable).
Parameter Correlation Coefficient p-Value
Age 0.43 0.004
Gender (M/F) 0.02 * 0.89
BMI 0.31 −0.16
Waist circumference −0.16 0.31
FBG 0.07 0.67
FBI 0.38 0.02
HbA1c 0.40 0.012
Total Cholesterol 0.02 0.89
HDL −0.04 0.78
LDL 0.02 0.88
Triglycerides 0.39 0.012
AST −0.08 0.61
ALT 0.04 0.80
T2D yes/no 0.33 * 0.039
NAFLD yes/no 0.41 * 0.01
NAS score 0.36 * 0.023
Table 3. Bivariate correlation analyses between circulating pro-NT levels and VAT gene expression
(Spearman’s coefficient).
Gene Correlation Coefficient p-Value
NTN1 −0.11 0.50
UNC5B 0.42 0.009
CAV1 0.11 0.50
IL8 −0.08 0.61
MIP1A 0.08 0.61
MIP2 0.11 0.50
TIMP1 0.15 0.38
GZMB −0.13 0.43
CASP3 −0.02 0.9
CASP7 0.09 0.58
PARP1 0.16 0.43
HIF-1α 0.41 0.011
WISP1 0.37 0.022
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4. Discussion
The main finding of this study is the relationship between higher pro-NT levels and histological
evidence of VAT inflammation in morbidly obese patients. Furthermore, in our study population,
circulating pro-NT also correlated with the presence of T2D and NASH, which represents a possible
biomarker of metabolic impairment in obesity. The existence of an independent association between
higher proNT levels and the presence and severity of NAFLD/NASH has been very recently
demonstrated by our group in a population of obese and non-obese individuals with and without
T2D [21].
In the present study, pro-NT levels positively correlate with triglycerides concentration,
which aligns with evidence from experimental models. NT administration was shown to directly
modulate lipid metabolism in rats [22].
VAT inflammation and the subsequent metabolic dysfunction are implicated in the development
of obesity-related complications such as systemic low-grade inflammation, insulin-resistance, and T2D.
In particular, VAT dysfunction has been recognized as determining ectopic fat distribution and NAFLD
in humans due to the aberrant FFAs and adipokine release from an unhealthy adipose cell tissue
under a stressful chronic caloric overload. However, whether VAT dysfunction is a requirement across
the lifespan of an obese individual has not been yet elucidated and neither genetic or environmental
factors potentially determining VAT dysfunction in obesity have been identified so far. Additionally,
the overall data on an integrated action of NT in regulating food intake and energy balance may
provide a pathophysiological explanation to the excess of cardiovascular risk associated with higher
pro-NT levels reported in several epidemiology studies [9,10]. Furthermore, NT exerts impact other
relevant factors controlling body weight such as leptin and ghrelin [4]. In addition, several metabolic
mediators might be potentially involved in NT regulation [23].
Therefore, increased pro-NT may significantly promote lipids absorption by inducing both directly
and indirectly, which includes favoring body weight gain, fat accumulation, and dysmetabolism.
Despite the cross-sectional design of this study, it does not allow to establish the causal relationship
of our findings. It is possible to hypothesize that NT is involved in the development of dysmetabolic
conditions likely through increased gut fat absorption and the induction of a pro-inflammatory milieu
in the adipose tissue. Moreover, since increased plasma pro-NT levels are associated with both VAT
inflammation and NAFLD [21], pro-NT measurement may represent a potential tool for a more
accurate risk stratification in obese patients as well as a novel success criterion for metabolic and
bariatric surgery [24].
Longitudinal studies are warranted in order to explore the potential role of pro-NT as a
determinant of VAT inflammation and related-metabolic diseases in obesity.
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